Inhibrx Biosciences, Inc.
INXB
NASDAQ Global Market15.86
USD
+1.94
- -
Return %
Stock
S&P500
1Y
13.94
26.53
3Y
-90.67
76.60
5Y
-90.67
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mark Paul Lappe
- Full Time Employees
- 166
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11025 North Torrey Pines Road La Jolla CA United States of America 92037
- IPO Date
- Apr 24, 2018
- Website
- inhibrx.com
- Similar Companies
- Business
- Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel biologics for the treatment of oncology and rare diseases. The company specializes in creating engineered protein therapeutics and biologic drugs, including bispecific antibodies, multispecific biologics, and antibody-drug conjugates aimed at immune-oncology and targeted cancer therapies. Its primary product candidates target various cancers and rare diseases using proprietary antibody engineering platforms. Inhibrx operates primarily within the biopharmaceutical industry and focuses on discovery, development, and commercialization of transformative biologic therapeutics. The company's product portfolio includes its proprietary technology platforms designed to develop treatments for solid tumors and hematologic cancers as well as rare genetic disorders. Its customer base includes pharmaceutical companies and healthcare providers, with operations centered in the United States and activities supporting global clinical trials. Founded in 2011, Inhibrx is headquartered in San Diego, California. The company has been actively expanding its pipeline and strategic partnerships in recent years to accelerate clinical development and broaden its therapeutic reach. However, there have been no publicly announced major corporate reorganizations, name changes, or significant funding rounds within the past 1-2 years as per the latest available information. Overall, Inhibrx Biosciences is dedicated to innovative biologics development using proprietary antibody engineering for oncology and rare disease treatments, with a growing pipeline and strategic collaborations to advance its clinical-stage assets from San Diego headquarters.